摘要
目的探讨核磁共振成像(MRI)全身弥散加权成像(WB-DWI)在评估乳腺癌术前实施新辅助化疗疗效中的应用价值。方法选取64例患者作为研究对象,对患者化疗前、化疗一个疗程结束时及化疗结束时分别行DWI成像检查,测量病灶变化及表观系数(ADC)值的变化。结果新辅助化疗64例,其中有效48例(75%),无效16例(25%)。化疗前ADC值和肿瘤最大径线值均与化疗结束时的数值差异显著(P<0.05)。化疗有效患者的ADC值升高情况显著高于化疗无效组患者(P<0.05)。结论乳腺癌术前实施WB-DWI具有可行性和临床价值。
Objective To explore the application value of magnetic resonance imaging (MRI) whole body-diffusion weighted imaging (WB-DWI) in evaluation of clinical effect of Preoperative neoadjuvant chemotherapy of breast cancer. Methods 64 patients were selected as research subject. DWI was used in patients before chemotherapy, at the end of one course chemotherapy and at the end of chemotherapy, and changes of nidus and apparent diffusion coefficient (ADC) value were tested. Results 48 cases were effective (75%), and 16 cases were ineffective in 64 cases of neoadjuvant chemotherapy. There had a significant difference in ADC value and maximum diameter line of tumor before and after chemotherapy (P 〈 0.05). The increase of ADC value of effective patients was significantly higher than that of ineffective patients (P 〈 0.05). Conclusion WB-DWI in preoperation of breast cancer has feasibility and clinical value.
出处
《中国医药科学》
2015年第15期165-167,共3页
China Medicine And Pharmacy